ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 497

Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry

Seung Min Jung1, Ji Yeon Lee1, Jung Hee Koh1, Seung-Ki Kwok2, Ji Hyeon Ju1, Chong-Hyeon Yoon1 and Sung-Hwan Park1, 1Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 2[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, Elderly, registry and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the mean age of patients with RA, the data in elderly patients are still limited. We aimed to investigate the treatment outcome and the risk factors for poor outcome in elderly patients with RA. 

Methods: This cross-sectional study analyzed the data of 1,227 patients with RA who were recruited for KOrean college of rheumatology BIOlogics (KOBIO) registry between 2013 and 2014. The demographic data, drugs, and disease activity were collected for all available participants. We compared the disease status between elderly patients (age ≥ 65) and younger patients (age < 65), and investigated the clinical factors affecting disease activity. 

Results: Of 1,227 patients in KOBIO registry, 244 patients with RA were aged 65 or over. The proportion of men was higher (p = 0.012), and the duration of disease was longer (p < 0.001) in elderly patients compared to younger patients. The prevalence of comorbid condition determined by Charlson Comorbidity Index and Elixhauser’s Comorbidity Measures was higher in elderly group (p = 0.001). Treatment of methotrexate was more frequent in younger group (p = 0.004), while use of other medications was comparable. More patients in elderly group had a high disease activity (disease activity score in 28 joints > 5.1, simple disease activity index > 40, and clinical disease activity index > 22), which was independently associated with longer duration of disease, presence of comorbidity, and non-use of methotrexate (p = 0.002, p < 0.001, and p = 0.029, respectively). Especially, diabetes was closely related with poor treatment outcome. 

Conclusion: This study suggests that disease activity might be insufficiently controlled in elderly patients with RA. The meticulous efforts would be required to reach therapeutic target of RA, regardless of age.


Disclosure: S. M. Jung, None; J. Y. Lee, None; J. H. Koh, None; S. K. Kwok, None; J. H. Ju, None; C. H. Yoon, None; S. H. Park, None.

To cite this abstract in AMA style:

Jung SM, Lee JY, Koh JH, Kwok SK, Ju JH, Yoon CH, Park SH. Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/treatment-outcomes-in-elderly-patients-with-rheumatoid-arthritis-results-from-a-nationwide-korean-biologics-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-outcomes-in-elderly-patients-with-rheumatoid-arthritis-results-from-a-nationwide-korean-biologics-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology